1
|
Feng C, Chu W, Lin P, Xu H, Chen X. Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes. Medicine (Baltimore) 2024; 103:e37839. [PMID: 38640269 PMCID: PMC11029982 DOI: 10.1097/md.0000000000037839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 02/20/2024] [Accepted: 03/18/2024] [Indexed: 04/21/2024] Open
Abstract
This study aimed to elucidate 1-year outcomes following switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration (wAMD). In this prospective, open-label, non-controlled clinical trial, 18 patients with wAMD who had multiple recurrences or persistent exudation despite intravitreal injections of anti-vascular endothelial growth factor agents (except aflibercept) received a 3-mg intravitreal aflibercept injection every 4 weeks. Each patient received 3 to 8 injections. The central retinal thickness and fibrovascular pigment epithelial detachment height decreased significantly at 1 month after initiation of the aflibercept injection, and the values were 146 and 163.2 μm, respectively, at the final visit. The morphological improvement was sustained. The intraretinal and subretinal fluid was completely absorbed at the end of the follow-up. The logMAR vision increased from baseline 0.68 to 0.59 (P < .05). No ocular or systemic adverse events occurred. The intravitreal injection of 3-mg aflibercept seems to be feasible in the treatment of wAMD unresponsive to other anti-vascular endothelial growth factor agents.
Collapse
Affiliation(s)
- Chengcheng Feng
- Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China
| | - Wenjuan Chu
- Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China
| | - Ping Lin
- Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China
| | - Haifeng Xu
- Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China
| | - Xiuli Chen
- Qingdao Eye Hospital, Shandong First Medical University, Qingdao, China
- State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University, Qingdao, China
| |
Collapse
|
2
|
Chow R, Biswas T, Liu H, Pryor DI, Chu W, Swaminath A, Chung HT, Schellenberg D, Grindrod N, Lee YY, Gaede S, Sachdeva R, Lock MI. Radiotherapy for Liver Cancer: An International Multi-Centre Pooled Analysis of 925 Cases. Int J Radiat Oncol Biol Phys 2023; 117:e319-e320. [PMID: 37785141 DOI: 10.1016/j.ijrobp.2023.06.2358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Primary and secondary liver cancer incidence is growing and has a poor prognosis. The standard use of radiation has been hampered by studies with a wide range of patients, different management protocols and varied outcomes. To overcome this heterogeneity in the literature, larger and higher-level trials are warranted, but, so far, have been difficult to implement. Therefore, pooled analyses may offer the best way to determine the benefit of radiation, identify treatment parameters needed to optimize treatment techniques, and identify patient factors that allow for better patient selection. MATERIALS/METHODS Patients with liver cancer treated by radiotherapy at centers in Canada, United States and Australia was pooled. Patient and treatment characteristics were noted, as well as the clinical outcomes of local control within 1 year, recurrence and mortality. Stepwise Cox proportional hazards models were used to identify significant predictors for recurrence and mortality. Patients were stratified by center, and primary versus metastatic disease. RESULTS A total of 925 patients were included in this study. Mean age was 67 years, and 45% had a primary diagnosis of hepatocellular carcinoma. 1-year local control rate was 80%. Median survival was 1.8 years (1.9 years for primary liver cancer, and 1.4 years for metastatic liver cancer). Higher total dose and BED was associated with better survival. Median time to recurrence was 1.5 years. Higher total dose was associated with lower risk of recurrence CONCLUSION: As one of the largest pooled analyses in hepatic cancer, this international multi-center study provides pragmatic data on clinical outcomes of patients receiving radiotherapy for liver cancer. This database may assist in better selection of patients for future studies and answer questions such as what is the optimal dose and which patients benefit from treatment.
Collapse
Affiliation(s)
- R Chow
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - T Biswas
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
| | - H Liu
- Princess Alexandra Hospital, Woolloongabba, Australia
| | - D I Pryor
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - W Chu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - A Swaminath
- Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
| | - H T Chung
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | | | | | - Y Y Lee
- Princess Alexandra Hospital, Greenslopes, QLD, Australia
| | - S Gaede
- Department of Medical Physics, Western University, London, ON, Canada
| | - R Sachdeva
- London Regional Cancer Program, London, ON, Canada
| | - M I Lock
- London Health Sciences Centre, London, ON, Canada
| |
Collapse
|
3
|
Tan VS, Correa RJM, Warner A, Ali M, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, Kwon YS, Morgan SC, Cury F, Teh BS, Mahadevan A, Kaplan ID, Chu W, Hannan R, Staehler M, Grubb W, Louie AV, Siva S. 5-Year Renal Function Outcomes after SABR for Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium of the Kidney (IROCK). Int J Radiat Oncol Biol Phys 2023; 117:S84. [PMID: 37784588 DOI: 10.1016/j.ijrobp.2023.06.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Renal cell carcinoma (RCC) presents uncommonly in patients with a congenital solitary kidney or prior contralateral nephrectomy. The objective of this study was to compare renal function outcomes of stereotactic ablative body radiotherapy (SABR) in patients with solitary vs. bilateral kidneys. MATERIALS/METHODS Patients with primary RCC with ≥2 years of follow-up at 12 participating International Radiosurgery Consortium for Kidney (IROCK) institutions were included. Patients with upper tract urothelial carcinoma or metastatic disease were excluded. Renal function was measured by estimated glomerular filtration rate (eGFR). For patients where eGFR was not recorded, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate eGFR based on known creatinine. Baseline characteristics and renal function outcomes were compared between solitary vs. bilateral kidneys. Multivariable logistic regression was used to identify factors predictive of eGFR decline ≥ 15 mL/min and any eGFR increase evaluated at 1-year post-SABR. RESULTS One hundred and ninety patients with solitary (n = 56) or bilateral kidneys (n = 134) underwent SABR and were followed for a median of 5.0 years (IQR: 3.4-6.8). Pre-SABR eGFR (mean ± SD) was similar in patients with solitary (61.1 ± 23.2 mL/min) vs. bilateral kidneys (58.0 ± 22.3 mL/min, p = 0.324). Mean tumor size was 3.70 ± 1.40 cm in solitary and 4.35 ± 2.50 cm in bilateral kidneys (p = 0.026). After SABR, an initial compensatory increase in eGFR was observed in both cohorts (22.7% solitary and 17.7% bilateral at 1 year). This compensatory increase persisted in patients with bilateral but not a solitary kidney (10.3% vs. 0% at 3-years and 21.1% vs. 0% at 5-years, respectively). At 5-years post-SABR, eGFR decreased by -14.5 ± 7.6 in solitary and -13.3 ± 15.9 mL/min in bilateral kidneys (p = 0.665). At all timepoints assessed, there were no significant differences in eGFR decline between solitary vs. bilateral cohorts (all p > 0.05). There were also no significant differences in post-SABR end-stage renal disease (7.1% vs. 6.7%) or dialysis (3.6% vs. 3.7%) in solitary vs. bilateral, respectively. Multivariable analysis demonstrated that increasing tumor size (OR per 1 cm: 1.57; 95% CI: 1.14-2.16, p = 0.006) and baseline eGFR (OR per 10 mL/min: 1.30; 95% CI: 1.02-1.66, p = 0.034) was more likely to be associated with eGFR decline ≥ 15 mL/min. There was no significant association between solitary vs. bilateral kidney and eGFR decline (OR: 1.22; 95% CI: 0.45-3.34, p = 0.693). CONCLUSION There was no observed difference between renal function outcomes in patients with a solitary vs. bilateral kidneys. While larger tumor size may increase the risk of eGFR decline post-SABR, treatment of a solitary kidney does not appear to increase the risk of renal dysfunction long-term.
Collapse
Affiliation(s)
- V S Tan
- London Regional Cancer Program, London, ON, Canada
| | - R J M Correa
- London Regional Cancer Program, London, ON, Canada
| | - A Warner
- London Regional Cancer Program, London, ON, Canada
| | - M Ali
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - A Muacevic
- University of Munich Hospitals, Munich, Germany
| | - L Ponsky
- University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
| | | | - S S Lo
- University of Washington School of Medicine, Seattle, WA
| | - H Onishi
- University of Yamanashi, Chuo, Japan
| | - A Swaminath
- Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
| | - Y S Kwon
- University of Texas Southwestern Medical Center, Dallas, TX
| | - S C Morgan
- The Ottawa Hospital Cancer Center, Ottawa, ON, Canada
| | - F Cury
- McGill University Health Centre, Montreal, QC, Canada
| | - B S Teh
- Houston Methodist Hospital, Houston, TX
| | - A Mahadevan
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York, NY
| | - I D Kaplan
- Beth Israel Deaconess Medical Center, Boston, MA
| | - W Chu
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - R Hannan
- University of Texas Southwestern Medical Center, Dallas, TX
| | - M Staehler
- University of Munich Hospitals, Munich, Germany
| | - W Grubb
- Augusta University, Augusta, GA
| | - A V Louie
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - S Siva
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| |
Collapse
|
4
|
Taggar A, Chu W, Chan K, Earle C, Wong S. Real-World Experience of Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Anal Cancer with Long-Term Follow up and Clinical Outcomes. Int J Radiat Oncol Biol Phys 2023; 117:e342. [PMID: 37785194 DOI: 10.1016/j.ijrobp.2023.06.2404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The standard treatment for epidermoid anal cancer (AC) is concurrent chemoradiation (CRT). Here we present real world evidence of the safety and outcomes of AC patients managed by IMRT and concurrent chemotherapy at a single academic cancer center. MATERIALS/METHODS We retrospectively reviewed the outcomes of 180 AC patients treated with definitive CRT between 2011 and 2018. Patients were managed according to a prospectively designed protocol of IMRT with radiation dose escalated according to tumor stage: 50.4, 55.8 and 63 Gy for T1, T2 and T3/T4 disease respectively, and 36 Gy for elective nodal RT. Involved nodes were given the same dose based on T category. Concurrent chemotherapy consisted of two cycles of mitomycin C (MMC, 12 mg/m2) and 5-fluorouracil (5FU, 1000 mg/m2/day x 4 days) given on week 1 and 5. There was no planned treatment break. Univariate and multivariate analysis for outcomes were performed using Cox proportional hazard method and likelihood ratio statistics. Overall survival (OS) disease free (DFS), colostomy-free survival (CFS) and local failure rates (LFR) were described by Kaplan-Meier methods. RESULTS There were 128 female and 52 male patients with a median age of 64 (IQR 55-74). The median size of the primary was 4.0 cm (0.6-11.0 cm). There were 18 T1, 91 T2, 38 T3 and 33 T4 lesions; 50.6% (91/180) of the patients had N0 disease. Thirteen (7.2%) did not receive concurrent chemotherapy, and 16 (8.9%) failed to complete treatment as planned. Forty-three (23.9%) patients had a treatment gap >5 (6-33) days. Eighteen of 147 (12%) with T1-3 disease failed locally, LF was observed in 13/33 (39%) T4 lesions (P = 0.0002). The 5-year OS, DFS, CFS and LFR were 85.1%, 75.6%, 87.6% and 15.5% respectively. On multivariate analysis, increasing age and N+ disease were significant for worse OS, and increasing size of the primary tumor was the only significant factor for worse DFS, CFS and LFR. Grade ≥3 acute toxicities were observed in 42.8% of patients, with grade ≥3 neutropenia and febrile neutropenia observed in 18.9% and 13.9% of patients respectively. Six patients (3.3%) died of acute toxicities. Thirteen (7%) patients experienced grade ≥3 late toxicities. CONCLUSION Size of the primary appears to be the most important determinant of outcome following standard CRT using IMRT for AC. Despite IMRT, almost 1 in 4 patients required a treatment break, and over 40% experienced grade ≥3 acute toxicities including neutropenia and febrile neutropenia. Future studies with RT dose escalation or de-escalation, stratifying patients based on tumor size, HPV status and molecular markers are necessary to improve outcomes and decrease treatment related toxicity.
Collapse
Affiliation(s)
- A Taggar
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - W Chu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - K Chan
- Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - C Earle
- Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - S Wong
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
5
|
Song J, Corkum MT, Loblaw DA, Chung HT, Tseng CL, Cheung P, Szumacher E, Liu SK, Chu W, Davidson MTM, Wronski M, Zhang L, Mamedov A, Morton G. Dosimetric Parameters Predictive of Treatment-Related Toxicity in High Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e438-e439. [PMID: 37785424 DOI: 10.1016/j.ijrobp.2023.06.1613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) High dose-rate (HDR) brachytherapy as monotherapy is an effective treatment for patients with low- and intermediate-risk prostate cancer and is increasingly being offered as a 2-fraction protocol. There is a lack of consensus on the optimal dosimetric planning parameters to use, or whether there is any benefit summating dosimetric parameters from more than one implant. Our goal is to determine planning parameters associated with disease control, toxicity and health-related quality of life (HRQOL). MATERIALS/METHODS Data were collected on 83 patients with low- and intermediate-risk prostate cancer who received 2 fractions of 13.5 Gy HDR brachytherapy without androgen-deprivation therapy as part of a randomized phase II clinical trial. An in-house deformable, registration algorithm was used to co-register and dose-summate the plans from both implants for each patient. Acute and late GU and GI toxicities were measured using CTCAE 4.0 and HRQOL was measured in urinary, bowel, sexual and hormonal domains using the EPIC scores. Treatment efficacy was assessed through PSA measurement and imaging with or without biopsy where indicated. Covariates included baseline clinical factors, disease characteristics and treatment dosimetric parameters. Cox proportional hazards was performed to evaluate covariates impact on treatment toxicity and efficacy, and logistic regression analysis evaluated covariates impact on HRQOL. RESULTS Among the 83 patients, median prostate volume was 46.7cm3. Median summated planning target volume receiving 100% prescription dose (PTV V100%) was 97.4%, median PTV V150% 42.4% and median PTV V200% 15.5%. Median highest dose to the 1cm3 rectum (D1cc) was 66.9% of the prescription dose and median rectum V80% was 0.008cm3. Median urethral D1cc was 99.0% of the prescription dose, median urethral Dmax 121.7% and median urethral D10% 116.2%. Grade ≥2 GI toxicity was uncommon (3.7% acute and 8.5% late), but grade ≥2 GU toxicity was reported in 73.2% (acute) and 46.3% (late) patients. Rectum D1cc and V80% were found to be significantly associated with grade 2 or higher acute GI toxicity, while use of a-blocker at baseline was associated with grade ≥2 acute GU toxicity. Similarly, use of a-blocker was associated with late grade ≥2 GU toxicity, but with no dosimetric associations. No other variables were associated with treatment-related toxicities. Only rectum D1cc was significantly associated with changes in bowel EPIC scores. Estimated 5-year biochemical disease-free survival was 93.9% and 5-year cumulative incidence of local failure was 3.8%. CONCLUSION HDR monotherapy with 27 Gy delivered in 2 fractions in treatment of prostate cancer is well tolerated with high rates of disease control and minimal toxicity. Dose summation between 2 fractions of HDR brachytherapy is feasible, with rectal dose predicting acute GI toxicity. The lack of association between dose metrics and urinary toxicity raises the potential for further dose escalation.
Collapse
Affiliation(s)
- J Song
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - M T Corkum
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - D A Loblaw
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - H T Chung
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - C L Tseng
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - P Cheung
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - E Szumacher
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - S K Liu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - W Chu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - M T M Davidson
- Department of Medical Physics, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - M Wronski
- Department of Medical Physics, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - L Zhang
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - A Mamedov
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - G Morton
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| |
Collapse
|
6
|
Ong WL, Davidson MTM, Cheung P, Chung HT, Chu W, Detsky J, Liu SK, Morton G, Szumacher E, Tseng CL, Vesprini D, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw DA. Dosimetric Predictors of Toxicities and Quality of Life Following Two-Fraction Stereotactic Body Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e425-e426. [PMID: 37785394 DOI: 10.1016/j.ijrobp.2023.06.1585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There is emerging interest in two-fraction stereotactic body radiotherapy (2#SBRT) for localized prostate cancer. However, there is limited data to guide organs at risk (OAR) dose constraints in 2#SBRT. We aim to identify dosimetric predictors of toxicities and quality of life (QoL) using real life patient data from two prospective 2#SBRT trials. MATERIALS/METHODS We included 60 patients who had 2#SBRT in the 2STAR (NCT02031328) and 2SMART (NCT03588819) phase 2 trials. The prescribed dose was 26Gy to the prostate +/- focal boost of 32Gy to the dominant intraprostatic lesions. Toxicities and QoL data were prospectively collected using CTCAEv4 and EPIC26 questionnaires. For QoL, we reported the minimal clinical important changes (MCIC), defined as changes in QoL score of >0.5 standard deviation from baseline QoL score. We evaluated the bladder, urethra, rectum, and penile bulb dosimetry (urethra dosimetry only available in 30 patients in 2SMART trial). Some of the dosimetric parameters were log-transformed to normalize the distribution. Cox regression was used to identify dosimetric predictors for acute and late grade ≥2 GU toxicities. Logistic regression was used to identify dosimetric predictors for late MCIC in urinary, bowel and sexual QoL domains. Backward stepwise selection was used to identify significant dosimetric parameters. For GU toxicities and urinary QoL, three additional clinical factors (age, prostate volume and IPSS) were included in the final model as confounding factors. Receiver operating characteristics curve was used to identify cut-off for significant dosimetric parameters. RESULTS The median follow-up for the cohort was 56 months (range: 39-78 months). The cumulative acute and late grade ³2 GU toxicities were 62% (37/60) and 57% (34/60) respectively. No bladder or urethra dosimetric parameter was associated with acute grade ≥2 GU toxicities. Bladder D0.5cc was significant predictor of late grade ≥2 GU toxicities in univariate model (P = 0.05), but not in multivariate model. Baseline IPSS score was the single strongest predictor for late grade ≥2 GU toxicities (HR = 1.9; 95% CI = 1.1-3.4; P = 0.03). For late QoL outcomes, there were 36% (21/58), 28% (16/58), and 29% (17/58) of patients with MCIC in urinary, bowel and sexual QoL domains respectively. Bladder V10Gy was associated with late urinary MCIC in multivariate model after adjusting for clinical confounders (HR = 2.6, 95% CI = 1.1-6.6; P = 0.04). 48% (14/29) and 24% (7/29) of patients with bladder V10Gy>13.9% and V10Gy≤13.9% respectively had late urinary MCIC. No rectum and penile bulb dosimetry parameters was identified to be associated with late bowel or sexual QoL. CONCLUSION Using real life patient data from prospective clinical trials with medium term follow-up, we identified statistically significant bladder dosimetry parameter predictive of late urinary QoL. This finding could be useful to guide OAR dose constraints in prostate 2#SBRT trials.
Collapse
Affiliation(s)
- W L Ong
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Alfred Health Radiation Oncology, Monash University Central Clinical School, Melbourne, Australia
| | - M T M Davidson
- Department of Medical Physics, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - P Cheung
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - H T Chung
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - W Chu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - J Detsky
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - S K Liu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - G Morton
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - E Szumacher
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - C L Tseng
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - D Vesprini
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - A Ravi
- Molli Surgical, Toronto, ON, Canada
| | - M McGuffin
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - L Zhang
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - A Mamedov
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - A Deabreu
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - M Kulasingham-Poon
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - D A Loblaw
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
7
|
Fan W, Tian H, Chen H, Chu W, Han L, Li P, Gao Z, Ji X, Lai M. Moisture Property and Thermal Behavior of Two Novel Synthesized Polyol Pyrrole Esters in Tobacco. ACS Omega 2023; 8:4716-4726. [PMID: 36777589 PMCID: PMC9910070 DOI: 10.1021/acsomega.2c06683] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 01/17/2023] [Indexed: 06/18/2023]
Abstract
To overcome the shortcomings of high relative humidity and harmful oxidation products from traditional humectants, excellent humectants and flavor precursors were reported herein. Glucosamine hydrochloride was used as the starting material for the cyclization, oxidation, and alkylation processes that produced pyrrole acid. Then, esterification occurred with polyol catalyzed by EDC and DMAP to give the target compounds 2-(2,3-dihydroxypropyl) 4-methyl 5-methyl-1-propyl-1H-pyrrole-2,4-dicarboxylate (Gpe) and (2-hydroxypropyl) 4-methyl 5-methyl-1-propyl-1H-pyrrole-2,4-dicarboxylate (Ppe). Nuclear magnetic resonance (1H NMR, 13C NMR), infrared spectroscopy (IR), and high-resolution mass recorded spectrometry (HRMS) were used to confirm the two novel polyol pyrrole ester compounds. When Gpe and Ppe were added to the tobacco shred, low-field nuclear magnetic resonance (LF-NMR) imaging was applied to assess the hygroscopicity and moisturizing capacity. Furthermore, thermogravimetry (TG) and pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS) techniques were applied to study their thermal behaviors. These results showed that the target compounds (Gpe and Ppe) are good humectants with thermal properties of high-temperature stability and flavor release.
Collapse
Affiliation(s)
- Wenpeng Fan
- Flavors
and Fragrance Engineering & Technology Research Center of Henan
Province, College of Tobacco Science, Henan
Agricultural University, Zhengzhou 450002, China
| | - Haiying Tian
- Technology
Center, China Tobacco Henan Industrial Co.,
Ltd., Zhengzhou 450000, China
| | - Hongli Chen
- Flavors
and Fragrance Engineering & Technology Research Center of Henan
Province, College of Tobacco Science, Henan
Agricultural University, Zhengzhou 450002, China
| | - Wenjuan Chu
- Technology
Center, China Tobacco Henan Industrial Co.,
Ltd., Zhengzhou 450000, China
| | - Lu Han
- Technology
Center, China Tobacco Henan Industrial Co.,
Ltd., Zhengzhou 450000, China
| | - Pengyu Li
- Flavors
and Fragrance Engineering & Technology Research Center of Henan
Province, College of Tobacco Science, Henan
Agricultural University, Zhengzhou 450002, China
| | - Ziting Gao
- Flavors
and Fragrance Engineering & Technology Research Center of Henan
Province, College of Tobacco Science, Henan
Agricultural University, Zhengzhou 450002, China
| | - Xiaoming Ji
- Flavors
and Fragrance Engineering & Technology Research Center of Henan
Province, College of Tobacco Science, Henan
Agricultural University, Zhengzhou 450002, China
| | - Miao Lai
- Flavors
and Fragrance Engineering & Technology Research Center of Henan
Province, College of Tobacco Science, Henan
Agricultural University, Zhengzhou 450002, China
| |
Collapse
|
8
|
Zhang H, Wang Y, Lin Y, Chu W, Luo Z, Zhao M, Hu J, Miao X, He F. A catalytic hairpin assembly-based Förster resonance energy transfer sensor for ratiometric detection of ochratoxin A in food samples. Anal Bioanal Chem 2023; 415:867-874. [PMID: 36564526 DOI: 10.1007/s00216-022-04479-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 12/04/2022] [Accepted: 12/07/2022] [Indexed: 12/25/2022]
Abstract
Ochratoxin A (OTA) poses severe risks to the environment and human health, making the development of an accurate and sensitive analytical method for OTA detection essential. In this study, a catalytic hairpin assembly (CHA)-based Förster resonance energy transfer (FRET) aptasensor was developed to detect OTA using carbon quantum dots (CDs) and 6-carboxy-fluorescein (FAM) as dual signal readout. In the presence of OTA, the aptamer specifically interacted with OTA to release the helper DNA (HP), which could open the hairpin structure of FAM-labeled hairpin DNA 1 (H1-FAM) modified on the surface of gold nanoparticles (AuNPs). CHA between H1-FAM and hairpin H2 labeled with CDs (H2-CDs) can release HP for the next cycle, resulting in the occurrence of FRET with CDs as the energy donor and FAM as the energy acceptor. According to the ratio of FCDs/FFAM, the proposed aptasensor showed a wide linear range from 5.0 pg/mL to 3.0 ng/mL and a low detection limit of 1.5 pg/mL for OTA detection. Moreover, satisfactory results were obtained for OTA detection in rice, suggesting the potential application of this sensor in food safety analysis.
Collapse
Affiliation(s)
- Hong Zhang
- College of Tobacco Science, Henan Agricultural University, Zhengzhou, Henan, 450002, People's Republic of China
| | - Yuli Wang
- College of Tobacco Science, Henan Agricultural University, Zhengzhou, Henan, 450002, People's Republic of China
| | - Yingtong Lin
- School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu, 221116, People's Republic of China
| | - Wenjuan Chu
- Technology Center, China Tobacco Henan Industrial Co., Ltd., Zhengzhou, Henan, 450000, People's Republic of China
| | - Zhen Luo
- Technology Center, China Tobacco Henan Industrial Co., Ltd., Zhengzhou, Henan, 450000, People's Republic of China
| | - Mingqin Zhao
- College of Tobacco Science, Henan Agricultural University, Zhengzhou, Henan, 450002, People's Republic of China
| | - Jiandong Hu
- Henan International Joint Laboratory of Laser Technology in Agriculture Sciences, Zhengzhou, Henan, 450002, People's Republic of China
| | - Xiangmin Miao
- School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu, 221116, People's Republic of China.
| | - Fan He
- College of Tobacco Science, Henan Agricultural University, Zhengzhou, Henan, 450002, People's Republic of China.
| |
Collapse
|
9
|
Glicksman RM, Cheung P, Korol R, Niglas M, Nusrat H, Erler D, Vesprini D, Swaminath A, Davidson M, Zhang L, Chu W. Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes. Clin Oncol (R Coll Radiol) 2023; 35:20-28. [PMID: 35948465 DOI: 10.1016/j.clon.2022.06.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 05/24/2022] [Accepted: 06/17/2022] [Indexed: 01/04/2023]
Abstract
AIMS To evaluate oncological and renal function outcomes of stereotactic body radiotherapy (SBRT) for medically inoperable patients with localised renal cell carcinoma. MATERIALS AND METHODS Consecutive patients treated with curative intent SBRT (30-45 Gy in five fractions or 42 Gy in three fractions) were included. Data on local control (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1), distant metastasis, impact on estimated glomerular filtration rate (eGFR) and proportional ipsilateral and contralateral renal functions (measured through renal scans) were collected. Univariate and multivariable analyses were conducted to determine association of variables with oncological and renal function outcomes. RESULTS Seventy-four patients were analysed. The median follow-up was 27.8 months (interquartile range 17.6-41.7). Fifty-seven per cent had tumours ≥ T1b. One-, 2- and 4-year cumulative incidence of local failure was 5.85, 7.77 and 7.77%, respectively. The cumulative incidence of distant metastasis at 2 years was 4.24%. On multivariable analysis, a lower planning target volume (PTV) mean dose (P = 0.019) and a larger PTV (P = 0.005) were significantly associated with the risk of developing local failure. A lower PTV maximum dose (P = 0.039) was significantly associated with the risk of developing distant metastasis. The median change in global eGFR (ml/min) from pre-SBRT levels was -7.0 (interquartile range -14.5 to -1.0) at 1 year and -11.5 (interquartile range -19.5 to -4.0) at 2 years. The proportion of ipsilateral (differential) renal function decreased over time from 47% of overall renal function pre-SBRT to 36% at 2 years, whereas the proportion of contralateral renal function correspondingly improved. On multivariable analysis, a higher volume of uninvolved renal cortex (P < 0.0001) was significantly associated with a smaller decrease in eGFR over time. CONCLUSION In this large institutional cohort, oncological outcomes of renal cell carcinoma treated with SBRT were favourable and a longitudinal decline in renal function in the ipsilateral kidney and compensatory increase in the contralateral kidney were observed. Clinical and dosimetric factors were significantly associated with oncological and renal function outcomes.
Collapse
Affiliation(s)
- R M Glicksman
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
| | - P Cheung
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - R Korol
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - M Niglas
- R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, Ontario, Canada
| | - H Nusrat
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - D Erler
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - D Vesprini
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - A Swaminath
- Juravinski Cancer Centre, Hamilton, Ontario, Canada; Department of Radiation Oncology, McMaster University, Hamilton, Ontario, Canada
| | - M Davidson
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - L Zhang
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - W Chu
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| |
Collapse
|
10
|
Liu J, Zhao JH, Chu W, Jiao HY, Hao GM, Gao J. [Retrospective analysis for 424 330 first-line screening results of non-invasive prenatal testing in Hebei province]. Zhonghua Fu Chan Ke Za Zhi 2022; 57:900-906. [PMID: 36562223 DOI: 10.3760/cma.j.cn112141-20220711-00453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Objective: To evaluate the effect of noninvasive prenatal testing (NIPT) as first-line screening in fetal chromosome aneuploidy screening practice, and to provide evidence for the prevention and control strategy of birth defects. Methods: Since July 2019, Hebei province had carried out the NIPT project providing first-line screening for eligible pregnant women in the area (except for those who were not applicable). Pregnant women with high risk received genetic counseling, prenatal diagnosis and intervention guidance. Low risk and false-positive ones received continuous detection and moved to prenatal diagnosis center for counseling and diagnosis if abnormities were discovered. All pregnant women were followed up to learn about pregnancy outcomes and newborn health status. Detection results and clinical data of pregnant women participating the NIPT project from July 2019 to July 2020 were collected. The detection results and effect of NIPT were analyzed. Results: (1) Basic information of the screened population: A total of 424 330 pregnant women were screened, and 423 596 were successfully detected, with a success rate of 99.83% (423 596/424 330). The age of pregnant women was (28.8±4.5) years old; the gestational age of screening was (16.6±2.3) weeks; the proportion of advanced-age pregnant women (≥35 years old) was 10.18% (43 132/423 596); in vitro fertilization-embryo transfer (IVF-ET) rate was 1.58% (6 713/423 596); the twin rate was 1.38% (5 849/423 596); the proportion of primipara was 34.23% (144 977/423 596). (2) Screening results and detection performance: totally, 325, 73 and 20 pregnant women were diagnosed with trisomy 21, 18 and 13; the sensitivity were 99.39%, 100.00% and 100.00%; the specificity were 99.98%, 99.99% and 99.98%; the positive predictive value were 75.76%, 68.87% and 21.51%, respectively. Besides, 249 190 pregnant women were received supplementary reports as well, and 255, 10 and 9 were confirmed for sex chromosome aneuploidy, other autosomal aneuploidy and deletion/duplication syndrome; the positive predictive value were 37.78%, 6.06% and 32.14%, respectively. The sensitivity of NIPT for target trisomy (trisomy 21, 18 and 13) screening in advanced-age, IVF-ET and twin pregnant women were 99.29%, 100.00% and 90.00%, respectively; the specificity were 99.93% for all; the positive predictive value were 82.25%, 61.54% and 69.23%, respectively. Conclusions: NIPT has a significant effect and good performance in the first-line screening of fetal chromosome aneuploidy in the whole population, which might provide reference for the improvement of birth defect prevention and control strategy.
Collapse
Affiliation(s)
- J Liu
- Business Management Department, Hebei Province Maternal and Child Care Center, Shijiazhuang 050031, China
| | - J H Zhao
- Clinical Inspection Center, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - W Chu
- Department of Reproduction and Genetics, Hebei General Hospital, Shijiazhuang 050051, China
| | - H Y Jiao
- Prenatal Diagnosis Branch Center, Maternal and Child Health Hospital of Shijiazhuang, Shijiazhuang 050000, China
| | - G M Hao
- Reproductive Center, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - J Gao
- Department of Reproduction and Genetics, Hebei General Hospital, Shijiazhuang 050051, China
| |
Collapse
|
11
|
Fan W, Chu W, Li Y, Han L, Li P, Tian H, Lai M, Ji X. Synthesis, Characterization and Thermal Behavior of N‐Substituted Pyrrole Esters. ChemistrySelect 2022. [DOI: 10.1002/slct.202203722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Wenpeng Fan
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou 450002 P. R. China
| | - Wenjuan Chu
- Technology Center of China Tobacco Henan Industry Co., Ltd Zhengzhou 450000 P. R. China
| | - Yaoguang Li
- Technology Center of China Tobacco Henan Industry Co., Ltd Zhengzhou 450000 P. R. China
| | - Lu Han
- Technology Center of China Tobacco Henan Industry Co., Ltd Zhengzhou 450000 P. R. China
| | - Pengyu Li
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou 450002 P. R. China
| | - Haiying Tian
- Technology Center of China Tobacco Henan Industry Co., Ltd Zhengzhou 450000 P. R. China
| | - Miao Lai
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou 450002 P. R. China
| | - Xiaoming Ji
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou 450002 P. R. China
| |
Collapse
|
12
|
Chu W, Taggar A, Ung Y, Chan K, Earle C, Karotki A, Pasetka M, Presutti J, Wong J, Wong S. Risk-Adjusted Chemoradiation according to Human Papilloma Virus Status for Anal Cancer: A Pilot Registry Study. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Correa R, Morton G, Chung H, Tseng C, Cheung P, Chu W, Liu S, McGuffin M, Shahid A, Davidson M, Ravi A, Helou J, Alayed Y, Zhang L, Mamedov A, Loblaw A. PO-1408 Two-fraction prostate SABR vs. two-fraction HDR brachytherapy: does dose heterogeneity matter? Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03372-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Fan W, Chu W, Tian H, Zhang Z, Feng Y, Gao Z, Cheng B, Ji X, Lai M. Synthesis and pyrolysis of two novel pyrrole ester flavor precursors. J Heterocycl Chem 2022. [DOI: 10.1002/jhet.4479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Wenpeng Fan
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province, College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou P. R. China
| | - Wenjuan Chu
- Technology Center China Tobacco Henan Industrial Co., Ltd. Zhengzhou P. R. China
| | - Haiying Tian
- Technology Center China Tobacco Henan Industrial Co., Ltd. Zhengzhou P. R. China
| | - Zhan Zhang
- Technology Center China Tobacco Henan Industrial Co., Ltd. Zhengzhou P. R. China
| | - Yingjie Feng
- Technology Center China Tobacco Henan Industrial Co., Ltd. Zhengzhou P. R. China
| | - Ziting Gao
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province, College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou P. R. China
| | - Biao Cheng
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province, College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou P. R. China
| | - Xiaoming Ji
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province, College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou P. R. China
| | - Miao Lai
- Flavors and Fragrance Engineering & Technology Research Center of Henan Province, College of Tobacco Science Henan Agricultural University 95 Wenhua Road Zhengzhou P. R. China
| |
Collapse
|
15
|
Cozma A, Lai W, McGuffin M, Erler D, Morton G, Chung H, Tseng C, Zhang L, Cheung P, Chu W, Vesprini D, Davidson M, Korol R, Ravi A, Loblaw D. Biochemical Failure and Toxicity of Magnetic Resonance Imaging Dose Painting to Dominant Intraprostatic Lesion in Prostate High Dose Rate Brachytherapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Glicksman R, Liu S, Cheung P, Vesprini D, Chu W, Chung H, Morton G, Deabreu A, Davidson M, Ravi A, Musunuru H, Helou J, Ho L, Zhang L, Loblaw D. Elective Nodal Ultra Hypofractionated Radiation for Prostate Cancer: Safety and Efficacy From Four Prospective Clinical Trials. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Cheung P, Tseng C, Chung H, Chu W, Vesprini D, Liu S, Morton G, Sahgal A, Soliman H, Myrehaug S, Detsky J, Szumacher E, Chung P, Helou J, Emmenegger U, Mamedov A, Shahid A, Zhang L, Loblaw D. Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP). Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Corkum M, Loblaw D, Chung H, Tseng C, McGuffin M, Davidson M, Paudel M, Wronski M, Cheung P, Chu W, Szumacher E, Zhang L, Mamedov A, Morton G. Dosimetric Predictors of Toxicity and Quality of Life Following Single Fraction High Dose-Rate Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Tree A, Hall E, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Brand D, Chan A, Dayes I, Brown S, Pugh J, Burnett S, Dufton A, Griffin C, Mahmud M, Naismith O, van As N, of the O. OC-0289 Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy). Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06839-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Wong CS, Chu W, Ashamalla S, Fenech D, Berry S, Kiss A, Koritzinsky M. Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial. Clin Transl Radiat Oncol 2021; 30:60-64. [PMID: 34401534 PMCID: PMC8350187 DOI: 10.1016/j.ctro.2021.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 07/09/2021] [Accepted: 07/18/2021] [Indexed: 12/15/2022] Open
Abstract
A prospective pilot phase I/II study on metformin given concurrently with neoadjuvant chemoradiation (CRT) in non-diabetic rectal cancer patients. Three patients had a clinical complete response (cCR) and did not have surgical resection. Of the 12 patients who underwent surgery, there were two pCRs. For the combined pCR/cCR rate of 33% (95% CI 19–47%), a total of 85 patients will be required to yield a 95% CI with a 10% margin of error. These pilot results are encouraging, and will serve to refine the design and conduct of a future phase 2 trial to determine whether adding metformin to CRT improves pCR/cCR rates.
Purpose Neoadjuvant radiotherapy with or without chemotherapy decreases the risk of local recurrence after surgery for rectal cancer. Emerging data suggest that diabetic patients on metformin may have improved cancer outcome after radiotherapy. A single institutional pilot study was performed to determine if metformin given concurrently with long course chemoradiation (CRT) may improve pathologic complete response (pCR) in non-diabetic rectal cancer patients. The study was designed to construct a confidence interval (CI) for the pCR rate to determine the sample size for a phase 2 trial. Methods Non-diabetic patients with biopsy confirmed rectal cancer deemed candidates for long course neoadjuvant CRT were invited to participate. Radiation consisted of 50.4 Gy in 28 daily fractions with concurrent daily capecitabine (825 mg/m2 twice daily). Participants self-administered metformin (500 mg of twice daily) 2 weeks prior to, during and for 4 weeks after CRT. Results A total of 16 patients were accrued. One patient withdrew from the study. Only grade 1 or 2 adverse events were observed. Three patients had a clinical complete response (cCR) and did not undergo surgery. Of the 12 patients who underwent surgery, there were two pCRs. For the combined pCR/cCR rate of 33% (95% CI 19–47%), a total of 85 patients will be required to yield a 95% CI with a 10% margin of error. Conclusions Adding metformin to neoadjuvant CRT for rectal cancer does not appear to enhance toxicities. These results will be used to refine the design and conduct of a future phase 2 trial to determine whether adding metformin to CRT improves pCR/cCR rates.
Collapse
Key Words
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- CBC, complete blood counts
- CI, confidence interval
- CRT, chemoradiation
- CT, computerized tomography
- CTCAE, Common Terminology Criteria for Adverse Events
- ICF, Informed Consent Form
- IHC-GCP, International Conference on Harmonization Good Clinical Practice
- MRI, magnetic resonance imaging
- Metformin
- Neoadjuvant chemoradiation
- Pathologic response
- REB, Research Ethics Board
- Rectal cancer
- TME, total mesorectal excision
- cCR, clinical complete response
- pCR, pathological complete response
Collapse
Affiliation(s)
- C S Wong
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
| | - W Chu
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
| | - S Ashamalla
- Division of Surgical Oncology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
| | - D Fenech
- Division of Surgical Oncology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
| | - S Berry
- Department of Oncology, Queen's University, Ontario, Canada
| | - A Kiss
- Institute for Clinical Evaluative Sciences, Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada
| | - M Koritzinsky
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada
| |
Collapse
|
21
|
Swaminath A, Cheung P, Glicksman RM, Donovan EK, Niglas M, Vesprini D, Kapoor A, Erler D, Chu W. Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort Study. Clin Oncol (R Coll Radiol) 2021; 33:468-475. [PMID: 33775496 DOI: 10.1016/j.clon.2021.03.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 02/02/2021] [Accepted: 03/04/2021] [Indexed: 01/31/2023]
Abstract
AIMS We report on the first prospective series of patient-reported quality of life (QoL) following stereotactic body radiation therapy (SBRT) for primary kidney cancer. MATERIALS AND METHODS Patients were treated on a multi-institutional prospective cohort study with 30-42 Gy SBRT in three or five fractions. QoL assessments were carried out using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-15 Palliative (EORTC-QLQ-C15-PAL), the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FACT FKSI-19) and the EuroQol-5D-3L tools at baseline, 1 week, and 1, 3 and 6 months post-treatment. QoL over time was analysed using linear mixed modelling, pairwise and anchor-based analyses. RESULTS Twenty-eight patients were included. No significant reduction in any QoL metric was observed on repeated measures. However, a trend to reduced EORTC global QoL and fatigue was observed at 1 week, with improvement over time in other symptom scores such as pain, appetite and nausea. On pairwise analysis, there were statistically significant reductions in global QoL at 1 week (with subsequent recovery) and dyspnoea at 6 months post-SBRT. Trends to improved pain, appetite and nausea were observed following SBRT. Less than half of patients reported stable or better EORTC global QoL at 1 week. For all other QoL and symptom scales, most patients had reported stable or better scores at all times, with a slight proportional improvement in emotional functioning, nausea, fatigue, pain and appetite, and a slight worsening of physical functioning and dyspnoea over time. CONCLUSIONS SBRT results in well-preserved QoL in the weeks to months following treatment for primary kidney cancer.
Collapse
Affiliation(s)
- A Swaminath
- Juravinski Cancer Centre, McMaster University, Department of Oncology, Hamilton, Ontario, Canada.
| | - P Cheung
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada
| | - R M Glicksman
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada
| | - E K Donovan
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada
| | - M Niglas
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada
| | - D Vesprini
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada
| | - A Kapoor
- St. Joseph's Healthcare, McMaster University, Institute of Urology, Hamilton, Ontario, Canada
| | - D Erler
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada
| | - W Chu
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Department of Radiation Oncology, Toronto, Ontario, Canada.
| |
Collapse
|
22
|
Sayer K, Whiteaway K, Dawson JO, Simpson J, Chu W. 57 Physical Activity Improvement in Elderly Hospitalised Patients at the Royal London: Exercise as Part of A Multimodal Intervention. Age Ageing 2021. [DOI: 10.1093/ageing/afab030.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Approximately 65% of elderly patients admitted to hospital experience some level of deconditioning during their stay. This can lead to longer length of stays, premature admissions to care homes and loss of function whilst in hospital (British Geriatrics Society). There is evidence that exercise can be safe and effective in reversing functional decline in this population. However, there is limited evidence into the effectiveness and feasibility of running a multi modal exercise intervention (eg. Dance and Exercise) on a busy elderly care ward in the UK.
Method
An 8-week inpatient programme consisting of a 60-minute exercise classes once a week and/or 60-minute dance class once a week started on the Older Person’s Wards at the Royal London. Primary outcome measures included: 5 x Sit To Stands (5xSTS) and Falls Efficacy Scale International (FES-I). Secondary measures; Rockwood score, Barthel Index, Elderly Mobility Score (EMS), Mood, 4AT and handgrip strength. Patient satisfaction scores were also recorded.
Results
23 patients were included in the analysis, 3 patients attended the dance class, 14 attended the exercise class and 5 attended both. In total 37 sessions were completed. The average score for all outcome measures improved except one after 8 weeks. The 5xSTS times improved by an average of 7.7 seconds and the FES-I score dropped by 3.9. The Barthel score increased by 5 points. Handgrip strength increased by 2.3 kg and 57% improved on their EMS. Mood improved from 5.4/10 to 6.0/10 and 4AT from 2.7 to 1.7. Overall, 70% of participants reported enjoying the classes and 90% said they would re-attend.
Conclusion
A multifactorial intervention including seated dance and exercise sessions showed significant improvements in mobility, fear of falling, cognition and functional tasks. Further work will look into the impact on length of stay and readmissions inpatient to hospital.
Collapse
Affiliation(s)
- K Sayer
- The Royal London Hospital, Wards 14E and 14F
| | - K Whiteaway
- The Royal London Hospital, Wards 14E and 14F
| | - J O Dawson
- The Royal London Hospital, Wards 14E and 14F
| | - J Simpson
- The Royal London Hospital, Wards 14E and 14F
| | - W Chu
- The Royal London Hospital, Wards 14E and 14F
| |
Collapse
|
23
|
Donovan E, Xie F, Chu W, Louie A, Kapoor A, Siva S, Swaminath A. Cost-Effectiveness of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) in the Treatment of Localized Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Cheung P, Patel S, North S, Sahgal A, Chu W, Soliman H, Ahmad B, Winquist E, Niazi T, Pantenaude F, Lim G, Heng D, Dubey A, Czaykowsky P, Wong R, Swaminath A, Morgan S, White J, Keshavarzi S, Bjarnason G. Stereotactic Radiotherapy for Oligoprogression in Metastatic Kidney Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Prospective Phase II Multi-Centre Study. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Hudson J, Chung H, Chu W, Taggar A, Davis L, Halet J, Law C, Singh S, Myrehaug S. Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Locke G, Pichardo S, Staruch R, McGuffin M, Partanen A, Wong S, Czarnota G, Hynynen K, Chu W. A Phase I Prospective Clinical Trial Using Volumetric Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) Hyperthermia (HT) Combined with Radiotherapy and Chemotherapy for Recurrent Rectal Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Wang L, Shen J, Zhang X, Lu H, Chu W. Retrospective analysis of the clinical effects of endoscopic mucosal dissection on treatment of early esophagogastric precancerous lesions. Clin Transl Oncol 2020; 23:731-737. [PMID: 32789667 DOI: 10.1007/s12094-020-02462-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Accepted: 07/17/2020] [Indexed: 02/07/2023]
Abstract
INTRODUCTION The purpose of this study was to conduct a retrospective study about the clinical effects of endoscopic mucosal dissection on the treatment of early esophagogastric precancerous lesions. METHODS A total of 132 patients with early esophagogastric precancerous lesions who were diagnosed and treated with concurrent surgery in our hospital from January 2018 to December 2019 were included in this retrospective study. Patients were divided into endoscopic mucosal resection (EMR) group (n = 58) and endoscopic submucosal dissection (ESD) group (n = 74) according to different surgical methods. The data in the two groups were compared and analyzed in terms of surgical indicators, treatment status and incidence of postoperative complications. RESULTS There were statistically significant differences between the two groups in the whole block cutting rate, fractional cutting rate and complete cutting rate (P < 0.05). The mean operation time of ESD group was significantly longer than that of EMR group (P < 0.05). There were no significant differences in the intraoperative bleeding rate, blood loss, average specimen area, length of hospital stay and treatment cost between the two groups (P > 0.05). The incidence and recurrence of postoperative complications, including bleeding, perforation and stenosis in the two groups, were observed within 1 year of postoperative follow-up. The incidence of complications in ESD group was slightly higher than that in EMR group, and the local recurrence rate in ESD group was lower than that in EMR group (P > 0.05). CONCLUSION ESD is an alternative surgical treatment for patients with early esophagogastric precancerous lesions.
Collapse
Affiliation(s)
- L Wang
- Department of Gastroenterology, Shanghai Jinshan Branch of the Sixth People's Hospital, Health Road No. 147, Zhujing Town, Jinshan District, Shanghai, 201500, China.
| | - J Shen
- Department of Gastroenterology, Shanghai Jinshan Branch of the Sixth People's Hospital, Health Road No. 147, Zhujing Town, Jinshan District, Shanghai, 201500, China
| | - X Zhang
- Department of Gastroenterology, Shanghai Jinshan Branch of the Sixth People's Hospital, Health Road No. 147, Zhujing Town, Jinshan District, Shanghai, 201500, China
| | - H Lu
- Department of Gastroenterology, Shanghai Jinshan Branch of the Sixth People's Hospital, Health Road No. 147, Zhujing Town, Jinshan District, Shanghai, 201500, China
| | - W Chu
- Department of Gastroenterology, Shanghai Jinshan Branch of the Sixth People's Hospital, Health Road No. 147, Zhujing Town, Jinshan District, Shanghai, 201500, China
| |
Collapse
|
28
|
Martell K, Mendez LC, Chung HT, Tseng CL, Alayed Y, Cheung P, Liu S, Vesprini D, Chu W, Wronski M, Szumacher E, Ravi A, Loblaw A, Morton G. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients. Radiother Oncol 2019; 141:149-155. [PMID: 31522882 DOI: 10.1016/j.radonc.2019.08.017] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 08/16/2019] [Accepted: 08/20/2019] [Indexed: 10/26/2022]
Abstract
PURPOSE/OBJECTIVE To report biochemical control associated with single fraction 15 Gy high-dose-rate brachytherapy (HDR-BT) boost followed by external beam radiation (EBRT) in patients with intermediate-risk prostate cancer. MATERIALS AND METHODS A retrospective chart review of all patients with intermediate-risk disease treated with a real-time ultrasound-based 15 Gy HDR-BT boost followed by EBRT between 2009 and 2016 at a single quaternary cancer center was performed. Freedom from biochemical failure (FFBF), cumulative incidence of androgen deprivation therapy use for biochemical or clinical failure post-treatment (CI of ADT) and metastasis-free survival (MFS) outcomes were measured. RESULTS 518 patients met the inclusion criteria for this study. Median age at HDR-BT was 67 years (IQR 61-72). 506 (98%) had complete pathologic information available. Of these, 146 (28%) had favorable (FIR) and 360 (69%) had unfavorable (UIR) intermediate-risk disease. 83 (16%) received short course hormones with EBRT + HDR. Median overall follow-up was 5.2 years. FFBF was 91 (88-94)% at 5 years. Five-year FFBF was 94 (89-99)% and 89 (85-94)% in FIR and UIR patients, respectively (p = 0.045). CI of ADT was 4 (2-6)% at 5 years. Five-year CI of ADT was 1 (0-3)% and 5 (2-8)% in FIR and UIR patients, respectively (p = 0.085). MFS was 97 (95-98)% at 5 years. Five-year MFS was 100 (N/A-100)% and 95 (92-98)% in FIR and UIR patients, respectively (p = 0.020). CONCLUSION In this large cohort of intermediate-risk prostate cancer patients, 15 Gy HDR-BT boost plus EBRT results in durable biochemical control and low rates of ADT use for biochemical failure.
Collapse
Affiliation(s)
- K Martell
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - L C Mendez
- University of Toronto, Department of Radiation Oncology, Canada; Western University, Department of Radiation Oncology, London, Canada; London Health Sciences Centre, Canada
| | - H T Chung
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - C L Tseng
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Y Alayed
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada; Division of Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - P Cheung
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - S Liu
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - D Vesprini
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - W Chu
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - M Wronski
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - E Szumacher
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - A Ravi
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - A Loblaw
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - G Morton
- University of Toronto, Department of Radiation Oncology, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada.
| |
Collapse
|
29
|
Loblaw D, Quon H, Ong A, Alayed Y, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A. Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): Efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.491] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Cheung P, Morton G, Chung H, Vesprini D, Chu W, Liu S, Tseng C, Sahgal A, Soliman H, Myrehaug S, Szumacher E, Chung P, Helou J, Emmenegger U, Erler D, Mamedov A, Chan S, Zhang L, Loblaw D. Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP). Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1886] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Soo YO, Abrigo J, Chu W, Leung KT, Fong WC, Li SH, Li R, Ng PW, Wong KK, Wong LKS, Leung TWH. Risk of intracerebral haemorrhage in patients with cerebral microbleeds taking warfarin for atrial fibrillation: a prospective study. Hong Kong Med J 2019; 25 Suppl 5:6-8. [PMID: 31416977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Open
Affiliation(s)
- Y O Soo
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
| | - J Abrigo
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong
| | - W Chu
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong
| | - K T Leung
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
| | - W C Fong
- Department of Medicine, Queen Elizabeth Hospital
| | - S H Li
- Department of Medicine, North District Hospital
| | - R Li
- Department of Medicine, Pamela Youde Nethersole Eastern Hospital
| | - P W Ng
- Department of Medicine and Geriatrics, United Christian Hospital
| | - K K Wong
- Department of Medicine, Yan Chai Hospital
| | - L K S Wong
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
| | - T W H Leung
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
| |
Collapse
|
32
|
Kim W, Assouline S, Bartlett N, Bosch F, Budde L, Cheah C, Gregory G, Hong J, Ku M, Marlton P, Matasar M, Nastoupil L, Panizo C, Sehn L, Tzachanis D, Chu W, Hernandez M, Kwan A, Li C, Sison I, Wei M, Yin S, Yousefi K, Yoon S. AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.15_2632] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- W.S. Kim
- Division of Hematology-Oncology, Department of Internal Medicine; Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul Republic of Korea
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montréal, QC Canada
| | - N.L. Bartlett
- Siteman Cancer Center; Washington University School of Medicine in St. Louis; St. Louis MO United States
| | - F. Bosch
- Department of Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - L.E. Budde
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte CA United States
| | - C. Cheah
- Linear Clinical Research and School of Medicine; University of Western Australia; WA Australia
| | - G.P. Gregory
- School of Clinical Sciences at Monash Health; Monash University; Clayton VIC Australia
| | - J. Hong
- Department of Oncology; ASAN Medical Center; Seoul Republic of Korea
| | - M. Ku
- Department of Haematology; St Vincent's Hospital, University of Melbourne; Melbourne VIC Australia
| | - P. Marlton
- Department of Medicine; University of Queensland School of Medicine and Princess Alexandra Hospital; Brisbane QLD Australia
| | - M. Matasar
- Lymphoma Service, Division of Hematologic Oncology, Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - L. Nastoupil
- Department of Lymphoma and Myeloma, Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center; Houston TX United States
| | - C. Panizo
- Haemotology and Haemotherapy Department; Clínica Universidad de Navarra; Pamplona Spain
| | - L.H. Sehn
- Medical Oncology; BC Cancer Centre for Lymphoid Cancer and University of British Columbia; Vancouver BC Canada
| | - D. Tzachanis
- Department of Medicine; University of California San Diego; La Jolla CA United States
| | - W. Chu
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - M.G. Hernandez
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - A. Kwan
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - C.C. Li
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - I. Sison
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - M.C. Wei
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - S. Yin
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - K. Yousefi
- Product Development, Biometrics, Biostatistics; Genentech, Inc.; South San Francisco CA United States
| | - S. Yoon
- Division of Hematology/Medical Oncology, Department of Internal Medicine; Seoul National University Hospital; Seoul Republic of Korea
| |
Collapse
|
33
|
Sehn L, Assouline S, Bartlett N, Bosch F, Diefenbach C, Flinn I, Hong J, Kim W, Matasar M, Nastoupil L, Schuster S, Shadman M, Yoon S, Bender B, Chu W, Hernandez G, Kwan A, McCall B, Sison I, Wang C, Wei M, Yin S, Yousefi K, Budde L. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP-UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.119_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L.H. Sehn
- Medical Oncology; BC Cancer Centre for Lymphoid Cancer and University of British Columbia; Vancouver BC Canada
| | - S. Assouline
- Division of Hematology; Jewish General Hospital; Montréal QC Canada
| | - N.L. Bartlett
- Siteman Cancer Center; Washington University School of Medicine; St. Louis MO United States
| | - F. Bosch
- Department of Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - C.M. Diefenbach
- Department of Hematology/Oncology; New York University Medical Center; Brooklyn NY United States
| | - I. Flinn
- Blood Cancer Research Program; Sarah Cannon Research Institute/Tennessee Oncology; Nashville TN United States
| | - J.Y. Hong
- Department of Oncology; ASAN Medical Center; Seoul Republic of Korea
| | - W.S. Kim
- Division of Hematology-Oncology; Department of Internal Medicine; Samsung Medical Center Seoul Republic of Korea
| | - M. Matasar
- Lymphoma Service; Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - L. Nastoupil
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Houston TX United States
| | - S.J. Schuster
- Department of Medicine; Division of Hematology-Oncology, University of Pennsylvania; Philadelphia PA United States
| | - M. Shadman
- Medical Oncology Division; Department of Medicine, Fred Hutchinson Cancer Research Center; Seattle WA United States
| | - S.S. Yoon
- Division of Hematology/Medical Oncology; Department of Internal Medicine, Seoul National University Hospital; Seoul Republic of Korea
| | - B. Bender
- Clinical Pharmacology Development; Genentech, Inc.; South San Francisco CA United States
| | - W. Chu
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - G.M. Hernandez
- Oncology Biomarker Development; Genentech, Inc.; South San Francisco CA United States
| | - A. Kwan
- Safety Science Oncology; Genentech, Inc.; South San Francisco CA United States
| | - B. McCall
- Clinical Pharmacology Development; Genentech, Inc.; South San Francisco CA United States
| | - I. Sison
- Clinical Operations; gRED, Genentech, Inc.; South San Francisco CA United States
| | - C. Wang
- Safety Science Oncology; Genentech, Inc.; South San Francisco CA United States
| | - M.C. Wei
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - S. Yin
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - K. Yousefi
- Product Development; Biometrics, Biostatistics, Genentech, Inc.; South San Francisco CA United States
| | - L.E. Budde
- Department of Hematology and Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center; Duarte CA United States
| |
Collapse
|
34
|
Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC. Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials. Clin Oncol (R Coll Radiol) 2019; 31:621-629. [PMID: 31126725 DOI: 10.1016/j.clon.2019.05.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 03/05/2019] [Accepted: 04/01/2019] [Indexed: 12/21/2022]
Abstract
AIMS We conducted a pooled analysis of four prospective stereotactic body radiotherapy (SBRT) trials of low- and intermediate-risk prostate cancer to evaluate the incidence of prostate-specific antigen (PSA) bounce and its correlation with the time-dose-fraction schedule. The correlation between bounce with PSA response at 4 years (nadir PSA < 0.4 ng/ml) and biochemical failure-free survival (BFFS) was also explored. MATERIALS AND METHODS The study included four treatment groups: 35 Gy/five fractions once per week (QW) (TG-1; n = 84); 40 Gy/five fractions QW (TG-2; n = 100); 40 Gy/five fractions every other day (TG-3; n = 73); and 26 Gy/two fractions QW (TG-4; n = 30). PSA bounce was defined as a rise in PSA by 0.2 ng/ml (nadir + 0.2) or 2 ng/ml (nadir + 2.0) above nadir followed by a decrease back to nadir. Patients with fewer than three follow-up PSA tests were excluded from the pooled analysis. RESULTS In total, 287 patients were included, with a median follow-up of 5.0 years. The pooled 5-year cumulative incidence of bounce by nadir + 2.0 was 8%. The 2-year cumulative incidences of PSA bounce by nadir + 0.2 were 28.9, 21, 19.6 and 16.7% (P = 0.12) and by nadir + 2.0 were 7.2, 8, 2.7 and 6.7% (P = 0.32) for TG-1 to TG-4, respectively. Multivariable analysis revealed that for nadir + 2.0, pre-treatment PSA (odds ratio 0.49; 95% confidence interval 0.26-0.97) correlated with PSA bounce. Although PSA bounce by nadir + 0.2 (odds ratio 0.10; 95% confidence interval 0.04-0.24) and nadir + 2.0 (odds ratio 0.29; 95% confidence interval 0.09-0.93) was associated with a lower probability of PSA response at 4 years, there was no association between bounce by nadir + 0.2 (hazard ratio 0.36; 95% confidence interval 0.08-1.74) or nadir + 2 (hazard ratio 1.77; 95% confidence interval 0.28-11.07) with BFFS. CONCLUSION The incidence of PSA bounce was independent of time-dose-fraction schedule for prostate SBRT. One in 13 patients experienced a bounce high enough to be misinterpreted as biochemical failure, and clinicians should avoid early salvage interventions in these patients. There was no association between PSA bounce and BFFS.
Collapse
Affiliation(s)
- S Roy
- Tom Baker Cancer Center, Department of Oncology, University of Calgary, Calgary, Canada
| | - A Loblaw
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - P Cheung
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - W Chu
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - H T Chung
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - D Vesprini
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - A Ong
- CancerCare Manitoba, University of Manitoba, Winnipeg, Canada
| | - A Chowdhury
- CancerCare Manitoba, University of Manitoba, Winnipeg, Canada
| | | | - G Pang
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - R Korol
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - M Davidson
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - A Ravi
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - B McCurdy
- CancerCare Manitoba, University of Manitoba, Winnipeg, Canada
| | - J Helou
- Princess Margaret Cancer Center, University of Toronto, Toronto, Canada
| | - L Zhang
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - A Mamedov
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - A Deabreu
- Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
| | - H C Quon
- Tom Baker Cancer Center, Department of Oncology, University of Calgary, Calgary, Canada.
| |
Collapse
|
35
|
Alayed Y, Cheung P, Chu W, Chung H, Davidson M, Ravi A, Helou J, Zhang L, Mamedov A, Commisso A, Commisso K, Loblaw A. PO-0840 Two StereoTactic Ablative Radiotherapy Treatments for Localized Prostate Cancer (2STAR). Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31260-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Chung H, Lang P, Kayvanrad M, Thompson R, Chu W, Gennatas E, Valdes G, Cheung P. EP-1453 Machine learning prediction of early distant progression after SBRT for colorectal cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31873-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Mendez L, Martell K, Chung H, Tseng C, Alayed Y, Cheung P, Liu S, Vesprini D, Chu W, Szumacher E, Ravi A, Loblaw A, Morton G. OC-0288 Long-term results of 15Gy HDRBT boost in intermediate risk-prostate cancer:Analysis of 500 + patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30708-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Martell K, Mendez LC, Chung H, Tseng CL, Zhang L, Alayed Y, Liu S, Vesprini D, Chu W, Paudel M, Cheung P, Szumacher E, Ravi A, Loblaw A, Morton G. Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer. Radiother Oncol 2019; 135:170-177. [PMID: 31015164 DOI: 10.1016/j.radonc.2019.03.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 03/06/2019] [Accepted: 03/10/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND PURPOSE To identify if, in intermediate risk prostate cancer (IR-PCa), the absolute percentage of biopsied tissue positive for pattern 4 disease (APP4) may be a predictor of outcome. MATERIALS AND METHODS 411 patients with IR-PCa were retrospectively reviewed. APP4 was calculated based on biopsy reports. Multivariable competing risk analysis was then performed on optimized APP4 cutpoints to predict for biochemical failure (BF), androgen deprivation use for BF (ADT-BF) and development of metastases (MD). RESULTS Median follow-up for the cohort was 5.2 (Inter Quartile Range: 2.9-6.6) years. Median baseline PSA was 7.3 (5.3-9.8) ng/mL. 234 (56.9%) patients had T1 and 177 (43.1%) had T2 disease. Median APP4 was 2.00 (0.75-7.50)%. 38 (9.3%) patients experienced BF. The optimal cutpoint of APP4 for BF was >3.3% with an area under the curve (AUC) of 0.66. 17 (4.1%) received ADT-BF. The ADT-BF cutpoint was >6.6% with an AUC of 0.72. Eight (2.0%) developed MD. The MD cutpoint was >17.5% with an AUC of 0.86. Using APP4 >3.3 vs ≤ 3.3, log-transformed baseline PSA ln(PSA) (HR 2.5, 1.1-6.1; p = 0.037) and APP4 (HR 2.3, 1.1-4.7; p = 0.031) predicted for BF. Using APP4 >6.6 vs ≤ 6.6, ln(PSA) (HR 4.2, 1.4-12.4; p = 0.010) and APP4 (HR 3.7, 1.4-10.0; p = 0.009) were predictive of ADT-BF. APP4 >17.5 vs ≤ 17.5 alone was predictive of MD (HR 25.7, 4.9-135.3; p < 0.001). CONCLUSION APP4 cutpoints of >3.3%, >6.6% and >17.5% were strongly associated with increased risk of BF, ADT-BF and developing MD respectively. These findings may inform future practice when treating IR-PCa but require external validation.
Collapse
Affiliation(s)
- K Martell
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - L C Mendez
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Western University, Department of Radiation Oncology, London, Canada; London Health Sciences Centre, London, Canada
| | - H Chung
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - C L Tseng
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - L Zhang
- Sunnybrook Health Sciences Centre, Toronto, Canada
| | - Y Alayed
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada; Division of Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - S Liu
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - D Vesprini
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - W Chu
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - M Paudel
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - P Cheung
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - E Szumacher
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - A Ravi
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - A Loblaw
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada
| | - G Morton
- University of Toronto, Department of Radiation Oncology, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada.
| |
Collapse
|
39
|
So HL, Chu W, Wang YH. Naphthalene degradation by Fe 2+/Oxone/UV - Applying an unconventional kinetics model and studying the reaction mechanism. Chemosphere 2019; 218:110-118. [PMID: 30471491 DOI: 10.1016/j.chemosphere.2018.11.091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 10/30/2018] [Accepted: 11/13/2018] [Indexed: 06/09/2023]
Abstract
This study shows the degradation of naphthalene (Nap) in aqueous solution using Oxone process mediated by Fe2+ with UV-A irradiation (FOU). To elucidate the role of different parameters, Fe2+/Oxone (FO), Fe2+/UV (FU), Oxone/UV (OU) and direct photolysis processes were studied, separately. The degradation efficiency under different dosage of Fe2+, Oxone, initial probe compound concentration and solution pH were evaluated. It is concluded that FOU process has significantly better degradation capacity and efficiency. More than 90% of 0.125 mM Nap was removed in 20 min, under the optimal conditions of FOU ([Fe2+]0 = 0.250 mM, [Oxone]0 = 0.250 mM, wavelength = 350 nm and pH = 2.8). A mathematical model is proposed to describe the two-stage reaction kinetics involving Oxone. To alleviate the problems of radical surge at the initial stage and a radical deficit at later stage, a stepwise addition of oxidants was conducted and achieved a higher removal performance. Besides, the decay pathways of Nap under FOU process were proposed by using LC-ESI/MS analysis. The TOC content was found to be increased initially and decreased after 2 h reaction. It is clarified that the TOC increment was contributed by the partially degraded intermediates rather than the persistent Nap, since the latter was not completely combustible in the TOC analyzer, demonstrating that the FOU process is effective in degrading Nap into more degradable products such naphthoic acids and aldehydes.
Collapse
Affiliation(s)
- H L So
- Department of Civil and Environmental Engineering, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong
| | - W Chu
- Department of Civil and Environmental Engineering, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
| | - Y H Wang
- Department of Civil and Environmental Engineering, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong
| |
Collapse
|
40
|
Wang H, Chu W, Kou YH, Zhang SY. Analysis of imaging characteristics of patent foramen ovale-related cryptogenic stroke. J BIOL REG HOMEOS AG 2019; 33:433-438. [PMID: 30972992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- H Wang
- Ultrasonic Department, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan, China
| | - W Chu
- Ultrasonic Department, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan, China
| | - Y H Kou
- Ultrasonic Department, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan, China
| | - S Y Zhang
- Ultrasonic Department, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan, China
| |
Collapse
|
41
|
Hopman H, Chan S, Chu W, Lu H, Lam L, Mak A, Kahn R, Neggers S. Resting-state fMRI biomarkers and effects of transcranial magnetic stimulation in treatment-refractory depression. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
42
|
Swaminath A, Niglas M, Cheung P, Erler D, Korol R, Blain J, Lukka H, Vesprini D, Chu W. Patient-Reported Quality of Life Following Stereotactic Body Radiation Therapy for Primary Kidney Cancer: Results from a Prospective Cohort Study. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.366] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Roy S, Loblaw D, Cheung P, Chu W, Chung H, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon H. PSA Bounce after Stereotactic Body Radiation Therapy for Prostate Cancer: Pooled Analysis from 4 SBRT Trials Evaluating Different Time-Dose-Fraction Schedules. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Cheung P, Thompson R, Chu W, Myrehaug S, Poon I, Sahgal A, Soliman H, Tseng C, Wong S, Ung Y, Abrahao A, Berry S, Chan K, Cheng S, Earle C, Erler D, Zhang L, Ko Y, Chung H. Stereotactic Body Radiation Therapy for Metastatic Colorectal Cancer: Comprehensive Review from a Large Academic Institution. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Niglas M, Cheung P, Swaminath A, Erler D, Korol R, Vesprini D, Chu W. Identifying Potential Predictors of Late Renal Toxicity after Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Prospective Cohort Study. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Al Hanaqta M, Niglas M, Jiang C, Erler D, Cheung P, Chu W, Chung H, Myrehaug S, Poon I, Sahgal A, Soliman H. Outcomes and Toxicity of Stereotactic Radiation Therapy for Metastatic Breast Cancer – A Retrospective Cohort Study. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
47
|
Correa R, Siva S, Staehler M, Warner A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh B, Lo S, Muacevic A, Louie A. Renal SABR in Patients with a Solitary Kidney: An Individual-Patient Pooled Analysis from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Prins F, Kerkmeijer L, Voort van Zyp J, Eppinga W, Heerkens H, Lagendijk J, Tijssen R, Vonken E, Kotte A, Barendrecht M, Chu W, Intven M. EP-1617: Development and evaluation of a MRI based delineation guideline for renal cell carcinoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31926-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
49
|
Yu H, Katsaros D, Biglia N, Shen Y, Loo L, Yu X, Lin H, Fu Y, Chu W, Fei P, Ni Y, Jia W, Deng X, Qian B, Wang Z. Abstract P5-07-03: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- H Yu
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - D Katsaros
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - N Biglia
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - Y Shen
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - L Loo
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - X Yu
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - H Lin
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - Y Fu
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - W Chu
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - P Fei
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - Y Ni
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - W Jia
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - X Deng
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - B Qian
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| | - Z Wang
- University of Hawaii Cancer Center; S. Anna Hospital, n 5 and After Azienda Ospedaliero-Universitaria; University of Torino School of Medicine; Shanghai Jiao Tong University
| |
Collapse
|
50
|
Xu C, Chu W, Cui L, Li M. Crystal structure of poly[(μ2-1,4-bis((2-ethyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)(μ2-isophthalato-κ4O,O′:O′′,O′′′)cadmium(II)], C34H30N4O4Cd. Z KRIST-NEW CRYST ST 2017. [DOI: 10.1515/ncrs-2017-0076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractC34H30N4O4Cd, monoclinic, P21/c (no. 14), a = 10.382(2) Å, b = 18.102(4) Å, c = 18.449(5) Å, β = 123.32(2)°, V = 2897.3(12) Å3, Z = 4, Rgt(F) = 0.0540, ωRref(F2) = 0.1069, T = 293(2) K.
Collapse
Affiliation(s)
- Chunying Xu
- Henan Key Laboratory of Function-Oriented Porous Materials, and College of Chemistry and Chemical Engineering, Luoyang Normal University, Luoyang, Henan, 471934, P. R. China
| | - Wenjuan Chu
- Henan Tobacoo Industry Limited Liaility Company of Anyang Cigarette Factory, Anyang, Henan, 455000, P. R. China
| | - Lu Cui
- Henan Key Laboratory of Function-Oriented Porous Materials, and College of Chemistry and Chemical Engineering, Luoyang Normal University, Luoyang, Henan, 471934, P. R. China
| | - Minghui Li
- Henan Key Laboratory of Function-Oriented Porous Materials, and College of Chemistry and Chemical Engineering, Luoyang Normal University, Luoyang, Henan, 471934, P. R. China
| |
Collapse
|